WASHINGTON (AP) — Dr. Vinay Prasad, a well-known critic of the pharmaceutical industry and COVID-19 policies, has been appointed to lead the U.S. Food and Drug Administration’s (FDA) program for vaccines and biotech drugs.

FDA Commissioner Dr. Marty Makary made the announcement on Tuesday, acknowledging Prasad’s “long and distinguished history in medicine.” This move marks a significant shift in leadership, as Prasad is stepping into a role traditionally held by a career scientist at the FDA, raising questions about how this might impact vaccine approval processes.

Prasad, who has long been vocal in his opposition to various pharmaceutical industry practices, is the latest figure from the medical and political fringes to join the federal government under President Donald Trump. His appointment, however, has sparked concerns over whether new therapies will face heightened scrutiny, potentially slowing down approval processes for vaccines and other critical treatments.

Prasad takes over from Dr. Peter Marks, the FDA’s previous vaccine chief, who resigned in March following disagreements with Health Secretary Robert F. Kennedy Jr. over vaccine safety issues. In a social media post, Prasad sharply criticized Marks, calling him “a bobblehead doll that just stamps approval.”

In interviews, Prasad has made his views on the FDA clear, suggesting that the agency’s current form may not be beneficial. Last year, during a podcast with former Republican presidential candidate Vivek Ramaswamy, Prasad boldly stated that Americans might be “better off” without the FDA as it stands.

Prasad, a professor at the University of California San Francisco, has a medical background in cancer and blood disorders. He first gained recognition in academic circles for scrutinizing cancer therapies, showing that many fast-tracked cancer drugs approved by the FDA had never been proven to improve patient outcomes. These drugs were often approved based on measures like tumor shrinkage, which is thought to be a predictive sign of long-term survival but does not guarantee actual improvements in patients’ lives.

The FDA has consistently defended this approach as a way to expedite the approval of medications for patients with serious or terminal conditions.

During the COVID-19 pandemic, Prasad gained wider attention for his criticisms of vaccine mandates, mask mandates, lockdowns, and the accelerated approval of booster shots from Pfizer and Moderna. His stance echoed that of other Trump appointees like Makary and National Institutes of Health (NIH) Director Jay Bhattacharya.

In 2022, Prasad and Makary co-authored a paper criticizing the recommendation for booster shots in teens and young adults, particularly males, due to concerns about the risk of myocarditis (a rare heart condition). The paper argued that mandating boosters for this group could cause more harm than good, though it was met with resistance from experts who noted that none of the authors were specialists in infectious diseases or vaccine reactions.

Angela Rasmussen, a virus expert at the University of Saskatchewan, expressed concern about Prasad’s appointment, predicting that it could harm vaccine access in the U.S. and hinder transparency in vaccine approvals. Rasmussen warned that Prasad’s leadership could lead to fewer approvals and a decrease in the public’s access to vaccines.

In recent years, Prasad has become a prominent voice in podcasts aligned with the “Make America Healthy Again” movement, which often criticizes the FDA for being too closely tied to the pharmaceutical industry.

Prasad’s appointment is sure to cause unease among drug and vaccine manufacturers, as they rely on the predictability and stability of the FDA’s standards to guide their lengthy and costly drug development processes.

Prasad’s leadership at the FDA will likely be a point of contention in the coming months, as debates over vaccine safety and pharmaceutical industry influence continue to shape public health discussions.

Source: AP News – Critic of drug industry and COVID-19 measures to lead FDA vaccine program

The post New FDA Vaccine Head Criticizes Pharmaceutical Industry and COVID-19 Measures appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

U.S. President Donald Trump plans to sign executive orders eliminating diversity, equity, and inclusion (DEI) initiatives from the military and reinstating thousands of service members who were discharged for refusing COVID-19 vaccines during the pandemic. This announcement was made by newly confirmed Defense Secretary Pete Hegseth on Monday.

Hegseth’s Controversial Confirmation

Hegseth, a decorated veteran and former Fox News personality, narrowly secured his confirmation as defense secretary despite strong opposition from Democrats and some Republicans. His appointment marks a significant victory for Trump, who faced criticism over nominating Hegseth for the role traditionally reserved for leaders with bipartisan support and extensive experience managing large organizations.

On his first day at the Pentagon, Hegseth stated:

“There are more executive orders coming.”

Hegseth’s Top Priority: Removing DEI from the Military

One of Hegseth’s primary goals is to remove DEI programs from the U.S. military, which he sees as divisive. For example, the Air Force announced it will continue using its instructional video about the Tuskegee Airmen, the first Black airmen in the U.S. military, but only after the material was reviewed to ensure compliance with Trump’s ban on DEI initiatives.

Hegseth’s agenda signals sweeping changes in how the military approaches training, diversity, and inclusion.

Reinstating Troops Discharged Over Vaccine Refusals

Another major focus of Trump’s executive orders will be to reinstate service members who were dismissed for refusing COVID-19 vaccines. During the pandemic, thousands of troops were removed from service due to their noncompliance with the vaccine mandate.

The decision to bring these troops back is expected to generate debate, as vaccine mandates had been a contentious issue both within the military and in broader political circles.

Pentagon Leadership and Potential Shake-ups

On his arrival at the Pentagon, Hegseth was welcomed by Air Force General C.Q. Brown, the top U.S. military officer. Brown had been a subject of criticism in Hegseth’s latest book, but the two appeared cordial during their public interaction.

When asked about the possibility of firing Brown, Hegseth humorously responded:

“I’m standing with him right now. I look forward to working with him,” while patting Brown on the back.

Despite this lighthearted moment, rumors of potential mass firings among senior military leadership persist. During his confirmation process, Hegseth repeatedly refused to rule out dismissals, fueling speculation about significant changes at the top levels of military leadership.

Divisive Appointment Sparks Debate

Hegseth’s nomination and confirmation have been highly divisive. Traditionally, the role of defense secretary has gone to individuals with extensive experience managing large organizations and a track record of bipartisan support. Critics argue that Hegseth’s close ties to Trump and his lack of comparable administrative experience make him a controversial choice for the position.

Looking Ahead

With Hegseth now in place as defense secretary, significant changes to the Pentagon and military policy are expected in the coming weeks. The removal of DEI initiatives, the reinstatement of troops dismissed over vaccine refusals, and potential restructuring among military leadership could reshape the future of the U.S. armed forces.

Trump’s executive orders and Hegseth’s policies are likely to spark widespread debate, both within the military and among the broader public.

Source

The post Trump to End DEI in Military and Reinstate Troops Removed Over Vaccines appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

A lawyer associated with Robert F. Kennedy Jr., Aaron Siri, has filed a petition asking the U.S. Food and Drug Administration (FDA) to revoke approval for the polio vaccine. This move, initiated in 2022 on behalf of the nonprofit Informed Consent Action Network (ICAN), has drawn significant attention and controversy. ICAN challenges vaccine safety and mandates, reflecting a skeptical stance on vaccination.

Trump and Kennedy’s Vaccine Views

President-elect Donald Trump has praised the polio vaccine as “the greatest thing,” yet expressed openness to reconsidering certain vaccines for children if deemed dangerous or not beneficial. In contrast, Kennedy, Trump’s pick to lead the Department of Health and Human Services (HHS), has emphasized informed choice over vaccine mandates. “People ought to have a choice, and that choice ought to be informed by the best information,” Kennedy stated in a recent interview with NBC News.

If confirmed as head of HHS, Kennedy would oversee the FDA and could potentially influence its decision-making process regarding the petition. The FDA, however, has maintained that it is reviewing the petition and cannot predict when the review will be completed.

Senate Leader’s Warning

Senate Minority Leader Mitch McConnell, a polio survivor, issued a stern warning, highlighting the life-saving impact of the polio vaccine. “Efforts to undermine public confidence in proven cures are not just uninformed—they’re dangerous,” McConnell said, advising Kennedy to distance himself from such controversies.

The Impact of Polio Vaccines

Polio vaccination is widely regarded as one of the most significant public health achievements. In the 1950s, polio paralyzed and killed thousands annually. The introduction of vaccines dramatically reduced its prevalence, bringing the world close to eradicating the disease.

Siri’s petition demands a “properly controlled and properly powered double-blind trial” to assess the inactivated polio vaccine’s safety. Critics argue this is unnecessary and misrepresents vaccine safety. Dr. Paul Offit of Children’s Hospital of Philadelphia countered, “You’re substituting a theoretical risk for a real risk. The real risks are the diseases.”

The Centers for Disease Control and Prevention (CDC) supports the safety of the inactivated polio vaccine, noting no serious adverse events have been documented, except rare allergic reactions.

Different Polio Vaccines and Risks

The United States transitioned from the oral polio vaccine (OPV), which uses a weakened live virus, to the inactivated polio vaccine (IPV) due to safety concerns. OPV carries a slight risk of causing paralysis but remains essential in regions where polio still circulates. IPV, administered via injection, eliminates this risk but does not create mucosal immunity, meaning it doesn’t prevent the virus from infecting or being shed by vaccinated individuals.

The Spread of Polio

Poliovirus spreads via the fecal-oral route, often through contaminated hands or surfaces. The oral vaccine’s weakened virus can also be shed and mutate in under-vaccinated populations, leading to vaccine-derived cases. In 2023, vaccine-derived strains caused 524 cases globally, a decline from 881 in 2022.

Conclusion

The debate over the polio vaccine underscores the ongoing tension between vaccine skepticism and public health advocacy. While proponents stress the vaccine’s critical role in eradicating a deadly disease, detractors like Siri and ICAN raise questions about regulatory processes and safety standards. The outcome of the FDA’s review will have significant implications for public health policy and vaccine confidence.

Source

The post Trump Praises Polio Vaccine Amid Kennedy’s Controversial Petition appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.